Inflammatory Bowel Diseases

Inflammatory Bowel Disease Expert and Harvard Medical School Faculty Dr. Hamed Khalili Joins Vivante Health’s Clinical Advisory Board

Retrieved on: 
Monday, February 26, 2024

CHICAGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Vivante Health , the employee benefit for GI care, announced the addition of Dr. Hamed Khalili to its Clinical Advisory Board today.

Key Points: 
  • CHICAGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Vivante Health , the employee benefit for GI care, announced the addition of Dr. Hamed Khalili to its Clinical Advisory Board today.
  • Dr. Khalili is a gastroenterologist and Director of Clinical Research at Massachusetts General Hospital, Crohn’s and Colitis Center and an Associate Professor at Harvard Medical School.
  • His research focuses on studying dietary and lifestyle factors and their relationship to the development and progression of inflammatory bowel diseases.
  • “Vivante Health is doing fantastic work to care for people with digestive conditions, particularly in the area of inflammatory bowel disease and other digestive conditions.

Neurenati Therapeutics Concludes a 1.2 Million $ Seed Financing Round to Develop NEU-001 as a Promising Therapy for Hirschsprung Disease

Retrieved on: 
Thursday, February 29, 2024

Neurenati Therapeutics is delighted to announce the successful closing of its seed funding round, securing 1.2 million $ from Genson Capital, on the 2024 Rare Disease Day.

Key Points: 
  • Neurenati Therapeutics is delighted to announce the successful closing of its seed funding round, securing 1.2 million $ from Genson Capital, on the 2024 Rare Disease Day.
  • Neurenati, a Québec-based biotech company, focuses on the development of various rare diseases therapies, including pediatric conditions.
  • Maxime Ranger, President and CEO of Neurenati Therapeutics commented, “Currently, surgery remains the only option to newborns with HSCR.
  • As fourth member of the Board, he joins Rodolphe Soret (cofounder), Benoit Doré (Axelys), and Maxime Ranger (Neurenati).

MRM Health Initiates Clinical Research in Parkinson’s Disease

Retrieved on: 
Tuesday, February 20, 2024

The clinical research is being conducted in close collaboration with Nimble Science and the University of Calgary, Canada.

Key Points: 
  • The clinical research is being conducted in close collaboration with Nimble Science and the University of Calgary, Canada.
  • The clinical study is expected to enroll up to 100 subjects, including an age-matched healthy volunteer cohort.
  • The trial will run in Calgary Parkinson’s Research Initiative (CaPRI) with Dr. Davide Martino and is registered on Clinicaltrials.gov with number NCT06003608.
  • MRM Health recently obtained positive phase 2a clinical data with MH002 in Ulcerative Colitis and has an ongoing clinical study in Pouchitis.

AbbVie Unveils New Data from Robust Gastroenterology Portfolio at the 19th Congress of European Crohn's and Colitis Organisation (ECCO)

Retrieved on: 
Monday, February 19, 2024

NORTH CHICAGO, Ill., Feb. 19, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that 17 AbbVie-sponsored abstracts, including new data from its inflammatory bowel disease (IBD) portfolio, have been accepted for presentation at the 19th Congress of European Crohn's and Colitis Organisation (ECCO) taking place in Stockholm, Sweden from February 21-24.

Key Points: 
  • The research spans risankizumab (SKYRIZI®) and upadacitinib (RINVOQ®) in both Crohn's disease (CD) and ulcerative colitis (UC).
  • "Despite continued advancements, many patients are still suffering from the debilitating effects of living with IBD," said Sofie Berg, Pharm.D, Ph.D., therapeutic area head, international immunology, International Medical Affairs, AbbVie.
  • "It is critically important that as the treatment paradigm shifts, the gastroenterology community shifts with it.
  • SKYRIZI® (risankizumab) is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.

CollPlant Issues Letter to Shareholders

Retrieved on: 
Thursday, February 15, 2024

Our long-term collaboration with AbbVie to develop a paradigm-shifting regenerative dermal and soft tissue filler continues to advance.

Key Points: 
  • Our long-term collaboration with AbbVie to develop a paradigm-shifting regenerative dermal and soft tissue filler continues to advance.
  • In June of last year, we announced the achievement of an important milestone under this collaboration which triggered a $10 million payment from AbbVie to CollPlant.
  • Per CollPlant's agreement with AbbVie, CollPlant has the potential to receive additional milestones and option products payments, as well as receive meaningful royalties on product sales.
  • In the second quarter of 2023, CollPlant hired a dedicated expert to lead our Environment, Social and Governance (ESG) effort.

Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023

Retrieved on: 
Tuesday, February 13, 2024

Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.

Key Points: 
  • Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.
  • Chris Cargill, President & CEO of Sosei Heptares, commented: “2023 has been a transformational year for Sosei Group and the progress made by our teams across all areas of the business has been exceptional.
  • Marketing approval for PIVLAZ® in South Korea – for the prevention of cerebral vasospasm and related conditions after aneurysmal subarachnoid hemorrhage (“aSAH”) securing.
  • A Phase 1 study of NBI-1117569 has begun and a Phase 1 study of NBI-1117567 is expected to begin in 2024.

Enthera Pharmaceuticals Appoints Lisa M. Olson as CEO and Announces Clinical Trial Progress with Ent001

Retrieved on: 
Tuesday, January 23, 2024

Dr. Olson joins Enthera’s management team with over two decades of leadership experience in the biopharmaceutical industry including a successful career at AbbVie.

Key Points: 
  • Dr. Olson joins Enthera’s management team with over two decades of leadership experience in the biopharmaceutical industry including a successful career at AbbVie.
  • “We are entering the new year with positive momentum in Enthera’s corporate and clinical evolution with Lisa’s appointment as CEO and important progress with Ent001.
  • We are thrilled to have her join as CEO,” said Silvano Spinelli, Chairman of the Enthera Board of Directors.
  • Based on this, Enthera has initiated a multiple ascending dose (MAD) Phase 1b clinical trial in patients with moderately to severely active UC.

New Study Shows SonarMD Drives 10X Reduction in Hospital Admissions and Emergency Visits Related to IBD

Retrieved on: 
Friday, January 26, 2024

CHICAGO and LAS VEGAS, Jan. 25, 2024 /PRNewswire/ -- Technology-enabled patient engagement leads to 10 times fewer hospital admissions and emergency department (ED) visits among patients with inflammatory bowel disease (IBD), according to new research presented at the seventh annual Crohn's & Colitis Congress®, a meeting convening the IBD experts to transform patient care. This finding underscores the importance of proactive patient engagement as the foundation for population health.

Key Points: 
  • The study examined claims data of over 1,000 patients with IBD between January 2022 and December 2022.
  • Eighty percent (939 patients) were enrolled in SonarMD's program and 20% (234 risk-matched patients) were not enrolled during the study period.
  • Researchers measured disease-related ED visits, inpatient hospital admissions and the use of therapeutics, including biologics.
  • SonarMD helps practices overcome the first challenge of managing patients with complex chronic disease — engagement," said Beth Houck, CEO of SonarMD.

Landos Biopharma to Present New Data on Immunometabolism at the 19th Annual Congress of the European Crohn’s and Colitis Organisation

Retrieved on: 
Monday, January 8, 2024

The abstracts highlight new and additional data on immunometabolism modulation by activating NLRX1 and PLXDC2 with novel agonists such as NX-13 and LABP-69.

Key Points: 
  • The abstracts highlight new and additional data on immunometabolism modulation by activating NLRX1 and PLXDC2 with novel agonists such as NX-13 and LABP-69.
  • The ECCO congress will take place February 21-24, 2024 in Stockholm, Sweden.
  • We are excited to present data from multiple studies including the impact of NX-13 on eosinophil infiltration and visceral hypersensitivity, as well as confirming its relevancy in multiple models and species.
  • Additionally, we are pleased to share new preclinical insights into the potential role of PLXDC2 in ulcerative colitis,“ said Fabio Cataldi, M.D., Executive Vice-President & Chief Medical Officer at Landos.

First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program

Retrieved on: 
Wednesday, December 27, 2023

The non-binding term sheet includes a low seven-figure upfront payment to First Wave BioPharma for rights to Niclosamide, as well as economics related to future milestones and royalties.

Key Points: 
  • The non-binding term sheet includes a low seven-figure upfront payment to First Wave BioPharma for rights to Niclosamide, as well as economics related to future milestones and royalties.
  • Additional details of the transaction will be disclosed upon finalization and execution of the definitive agreement.
  • The drug is a potential non-steroidal anti-inflammatory therapy for the treatment of mild-to-moderate inflammatory bowel diseases (IBD).
  • Intellectual property for niclosamide formulations governing composition of matter and methods of use extends beyond 2040.